Nature communications · 2021
Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lapuente Dennis, Fuchs Jana, Willar Jonas, Vieira Antão Ana, Eberlein Valentina, Uhlig Nadja, Issmail Leila, Schmidt Anna, Oltmanns Friederike, Peter Antonia Sophia, Mueller-Schmucker Sandra, Irrgang Pascal, Fraedrich Kirsten, Cara Andrea, Hoffmann Markus, Pöhlmann Stefan, Ensser Armin, Pertl Cordula, Willert Torsten, Thirion Christian, Grunwald Thomas, Überla Klaus, Tenbusch Matthias
Аннотация
Several effective SARS-CoV-2 vaccines are currently in use, but effective boosters are needed to maintain or increase immunity due to waning responses and the emergence of novel variants. Here we report that intranasal vaccinations with adenovirus 5 and 19a vectored vaccines following a systemic plasmid DNA or mRNA priming result in systemic and mucosal immunity in mice. In contrast to two intramuscular applications of an mRNA vaccine, intranasal boosts with adenoviral vectors induce high levels of mucosal IgA and lung-resident memory T cells (TRM); mucosal neutralization of virus variants of concern is also enhanced. The mRNA prime provokes a comprehensive T cell response consisting of circulating and lung TRM after the boost, while the plasmid DNA prime induces mostly mucosal T cells. Concomitantly, the intranasal boost strategies lead to complete protection against a SARS-CoV-2 infection in mice. Our data thus suggest that mucosal booster immunizations after mRNA priming is a promising approach to establish mucosal immunity in addition to systemic responses.